Skip to content

Evaluating the effect of nebulizing colistine with nebulizing colistin-fosfomycin in comparison to nebulizing colistine in Ventillator-Associated Pneumonia with multidrug-resistant Acinetobacter Baumanii in Alzahra Intensive Care Units

Evaluating the effect of nebulizing colistine with nebulizing colistin-fosfomycin in comparison to nebulizing colistine in Ventillator-Associated Pneumonia with multidrug-resistant Acinetobacter Baumanii in Alzahra Intensive Care Units

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171230038142N12
Enrollment
78
Registered
2020-02-23
Start date
2019-08-23
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventillator-Associated Pneumonia. Ventilator associated pneumonia

Interventions

Intervention 1: Intervention group: The first group is treated with inhaled Colistin, along with meropenem and intravenous Colistin. The study included 39 patients with ventilator pneumonia whose resp

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patient hospitalization in ICU Age between 20 and 85 Diagnosis of ventilator pneumonia for the patient Diagnosis of colistin sensetive Acinetobacter baumannii Patient satisfaction

Exclusion criteria

Exclusion criteria: Diagnosis Another concomitant disease The patient died before the response Start treatment of acinetobacter

Design outcomes

Primary

MeasureTime frame
Duration of treatment. Timepoint: Upon completion of treatment and response to treatment. Method of measurement: Counting the days of hospitalization and receiving treatment until the response arrives.;Illness severity. Timepoint: Before and after taking the drug. Method of measurement: Based on CPIS criteria.;Response to treatment. Timepoint: Before and after taking the drug. Method of measurement: Based on microbial eradication criteria.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtusa Hakami Fafd

Esfahan University of Medical Sciences

a.hakamifard@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026